요약정보
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
- Resource Type
- Academic Journal
- Authors
- Ghilardi G; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Fraietta JA; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Gerson JN; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Van Deerlin VM; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Personalized Diagnostics, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Morrissette JJD; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Personalized Diagnostics, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Caponetti GC; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Paruzzo L; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Harris JC; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Chong EA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Susanibar Adaniya SP; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Svoboda J; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Nasta SD; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Ugwuanyi OH; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Landsburg DJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Fardella E; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Waxman AJ; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Chong ER; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Patel V; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Pajarillo R; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Kulikovskaya I; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lieberman DB; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Personalized Diagnostics, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Cohen AD; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Levine BL; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Stadtmauer EA; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Frey NV; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Vogl DT; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Hexner EO; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Barta SK; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Porter DL; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Garfall AL; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA.; Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; June CH; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Ruella M; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.
- Source
- Publisher:
Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN:10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE - Subject
- Language
- English